Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) --  Faruqi & Faruqi, LLP, a ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Rezolute, Inc. (Nasdaq: RZLT) for potential securities law violations. Investors who have lost money in their Rezolute, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/rzlt. What is this all about? Shares of Rezolute fell over 85 percent on December 11, after the company announced that its Phase 3 sunRIZE study in congenital hyperi ...

Key Takeaways Rezolute stock plunged after phase III data showed ersodetug failed to meet the primary goal in the HI study.RZLT's top dose cut HI events ~45%, but placebo improved ~40%, leaving results not statistically significant.RZLT is reviewing data, planning FDA talks, and advancing ersodetug in tumor-induced HI via the upLIFT study.Shares of Rezolute (RZLT) have plummeted 79.2% so far in December. The massive stock price crash was observed after RZLT reported disappointing top-line data from a late-s ...

Rezolute, Inc. shares tumbled sharply on December 11, 2025, as investors reacted to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, its lead drug candidate for treating congenital hyperinsulinism. The study failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant versus placebo, To learn more about the Rezolute investigation, go to www.faruqilaw.com/RZLT or call F ...

The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI"). The news, analyst moves, and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Rezolute may have previously misled investors about erso's efficacy and commercial prospects. SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as ...

Rezolute, Inc. (RZLT) has been beaten down lately with too much selling pressure. While the stock has lost 81.8% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of ...

Group 1 - Rezolute, Inc. shares experienced a significant decline of approximately 85-90% following disappointing results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug, which failed to meet primary and key secondary endpoints [4][5] - The highest dose in the trial showed reductions in hypoglycemia events that were not statistically significant compared to placebo, leading to investor concerns [4] - Trading of Rezolute's stock was halted under Nasdaq's volatility controls due to the drastic drop in share price, which fell from around $10.94 to an intraday low near $0.90 [5] Group 2 - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. for investors who suffered significant losses [2] - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3] - Investors are encouraged to contact the firm to discuss their legal rights and options following the stock's decline [1]

Core Viewpoint - Rezolute, Inc. (NASDAQ: RZLT) experienced a significant decline in share price, falling over 85% after the failure of its Phase 3 sunRIZE study in congenital hyperinsulinism, which did not meet its primary or key secondary endpoints. This has raised concerns about potential securities law violations due to misleading statements made by the company regarding earlier data and program outlook [2][4]. Group 1: Company Performance - The share price of Rezolute, Inc. dropped more than 85% on December 11, 2025, following the announcement of the failed clinical trial results [2]. - The Phase 3 sunRIZE study aimed at treating congenital hyperinsulinism did not achieve its primary or key secondary endpoints, leading to investor losses [2]. Group 2: Legal Investigation - Block & Leviton is investigating Rezolute, Inc. for potential securities law violations and may file an action to recover losses for affected investors [4]. - Investors who purchased common stock in Rezolute, Inc. and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their shares [3]. Group 3: Investor Support - Block & Leviton encourages investors who have lost money to contact them for assistance in recovering losses [5]. - The firm is recognized as a leading securities class action firm, having recovered billions for defrauded investors through litigation [7].

Core Viewpoint - Rezolute, Inc. experienced a dramatic decline in share price, dropping as much as 90% after announcing the failure of its Phase 3 sunRIZE trial for the drug ersodetug, which was intended to treat hypoglycemia caused by hyperinsulinism [1][4] Company Performance - The Phase 3 trial results indicated that the drug did not meet its primary endpoint, and the reduction in hypoglycemia events was not statistically significant compared to placebo [3] - The secondary endpoint, which assessed the change in average daily percent time in hypoglycemia, also failed to show significant results compared to placebo [3] Market Reaction - Following the announcement, Rezolute's share price plummeted, prompting analysts to downgrade the stock rating from outperform to neutral and reduce the price target from $12 to $1 [4] - The market's swift reaction reflects investor disappointment and concerns regarding the company's previous assurances about the drug's efficacy and market potential [2][4] Legal Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Rezolute misled investors about the efficacy and commercial prospects of ersodetug [2][4] - The firm is encouraging investors who suffered losses to come forward and is seeking information from individuals who may assist in the investigation [2][5]